Tri Locum Partners LP Makes New $9.58 Million Investment in Illumina, Inc. $ILMN

Key Points

• Tri Locum Partners LP has invested approximately $9.58 million in Illumina, acquiring 120,729 shares, which now represents about 4.9% of its portfolio.
• Illumina's stock has received mixed ratings from analysts, with target prices ranging from $94.00 to $126.00 and an average consensus price target at $123.17.
• In its latest quarterly earnings, Illumina reported an EPS of $1.19, exceeding estimates, though its revenue declined by 4.8% year-over-year.

Tri Locum Partners LP purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 120,729 shares of the life sciences company's stock, valued at approximately $9,579,000. Illumina accounts for about 4.9% of Tri Locum Partners LP's holdings, making the stock its 10th biggest holding. Tri Locum Partners LP owned 0.08% of Illumina as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. bought a new stake in shares of Illumina during the first quarter valued at approximately $376,000. BNP Paribas Financial Markets increased its holdings in shares of Illumina by 49.9% during the first quarter. BNP Paribas Financial Markets now owns 884,896 shares of the life sciences company's stock valued at $70,208,000 after acquiring an additional 294,609 shares in the last quarter. Beck Bode LLC increased its holdings in shares of Illumina by 51.9% during the first quarter. Beck Bode LLC now owns 4,342 shares of the life sciences company's stock valued at $344,000 after acquiring an additional 1,484 shares in the last quarter. Ieq Capital LLC increased its holdings in shares of Illumina by 141.3% during the first quarter. Ieq Capital LLC now owns 68,798 shares of the life sciences company's stock valued at $5,458,000 after acquiring an additional 40,291 shares in the last quarter. Finally, 53 House LLP grew its holdings in Illumina by 71.2% during the first quarter. 53 House LLP now owns 152,073 shares of the life sciences company's stock worth $12,065,000 after buying an additional 63,249 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of ILMN stock traded up $0.79 on Monday, hitting $99.96. 1,009,106 shares of the stock were exchanged, compared to its average volume of 1,544,262. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $15.36 billion, a PE ratio of 12.65, a P/E/G ratio of 2.25 and a beta of 1.43. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The firm's 50 day moving average is $99.10 and its two-hundred day moving average is $88.47.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Barclays upped their price target on Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Evercore ISI upped their price target on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Robert W. Baird upped their price target on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Wall Street Zen downgraded Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, Morgan Stanley upped their price target on Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Six equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $123.17.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.